Rome Therapeutics raises $77m for junk DNA-targeting drugs
pharmaphorum
SEPTEMBER 14, 2021
The Cambridge, Massachusetts biotech is focusing specifically on the 60% of DNA sequences that repeat themselves hundreds or thousands of times in the genome, known as the ‘repeatome’, that could contain targets for cancer and autoimmune disorders. That muffles the immune system response and allows the cancer to grow.
Let's personalize your content